spacer
The Healthcare Sales & Marketing Network celebrates 20 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Ceftobiprole 

 HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 3 May 2010
Basilea's Toctino(R) receives marketing authorization in Italy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Dec 2009
FDA Issues Complete Response Letter for Ceftobiprole
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Nov 2009
Basilea's Toctino(R) receives marketing authorization in Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Oct 2009
Basilea's Toctino(R) receives marketing authorization in Switzerland
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 5 May 2009
Basilea's Toctino(R) receives marketing authorization in Spain
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 29 Apr 2009
Basilea's Toctino(R) Receives Marketing Authorization in Netherlands
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 17 Mar 2009
Basilea's Toctino(R) receives marketing authorization in Austria
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Mar 2009
Basilea's Toctino(R) Receives Marketing Authorization in Belgium and Luxemburg
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 24 Feb 2009
Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) clinical studies
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Dec 2008
Basilea Pharmaceutica opens U.S. phase III study on alitretinoin for the treatment of severe chronic hand eczema
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Nov 2008
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2008
Zevtera(TM) (ceftobiprole medocaril), the novel anti-MRSA broad-spectrum antibiotic, receives a positive opinion from the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Oct 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in France
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 15 Oct 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in Finland
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 22 Sep 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in Denmark
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 8 Sep 2008
Basilea's Toctino(R) (alitretinoin) receives first national marketing authorization in the UK
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Mar 2008
FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2008
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Oct 2007
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 18 Sep 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jul 2007
Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
Swiss Regulatory Authority Grants Accelerated Assessment of Planned Market Authorization Application for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2007
Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 May 2007
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2007
Basilea Reports Positive Phase III Results for Alitretinoin
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
Basilea Announces Start of Phase III Program for Isavuconazole, Its Third Investigational Drug to Reach Pivotal Trials
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Basilea to Co-Promote Ceftobiprole
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
Basilea Reports Excellent Pivotal Data for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Investigational Antibiotic, at ICAAC
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2006
Basilea Announces Positive Phase III Results for Ceftobiprole, its First-In-Class Anti-MRSA Cephalosporin
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
Ceftobiprole
(Password required)
RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.